Burleigh Dabney, MD
Internal Medicine · Augusta, GANPI 1548899586
Payments from drug & device makers
Across 27 payments — averaging $20.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$57
- Merck$56
- Takeda Pharmaceuticals U.S.A., Inc.$45
- Incyte Corporation$38
- EMD Serono, Inc.$28
- Edwards Lifesciences$27
- plus $293 from 14 others
What the payments were for
- Food & beverage$545100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 3 | $57 |
| Merck | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $45 |
| Incyte Corporation | 2 | $38 |
| EMD Serono, Inc. | 2 | $28 |
| Edwards Lifesciences | 1 | $27 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $26 |
| AbbVie | 1 | $24 |
| Genentech USA, Inc. | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Novartis | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Morphosys, US Inc. | 1 | $19 |
| Dendreon Pharmaceuticals LLC | 1 | $19 |
| Johnson & Johnson | 1 | $17 |
| Deciphera Pharmaceuticals Inc. | 1 | $15 |
| Amgen | 1 | $14 |
How this compares
$545 in reported general payments places this provider in the 55th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cefdinir | 23 | $290 |
| Losartan Potassium | 28 | $215 |
| Metoprolol Tartrate | 24 | $155 |
| Methylprednisolone | 11 | $120 |
| Hydralazine Hcl | 16 | $112 |
| Atorvastatin Calcium | 14 | $76 |
| Amlodipine Besylate | 24 | $59 |
| Pantoprazole Sodium | 11 | $59 |
| Furosemide | 14 | $27 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Augusta
- Jon GibbsAugusta$172K
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.